Activation of EGFR/Erk1/2 and JAK could enhance invasiveness of cisplatin-resistant ovarian cancer cells in vitro, and the inhibition of both EGFR and JAK appeared to be an efficient approach to treat human ovarian cancer [85, 86]. Here, EGFR is linked to ovarian carcinoma.